The FDA's Circulatory System Devices Panel recommended that the cardiac resynchronization therapy defibrillator (CRT--D), developed by Boston Scientific, be approved for use in patients with mild heart failure in the United States. If the device is approved by the FDA, nearly 4 million more Americans could be candidates for treatment with the CRT-D.
Read »Navigation
User login
Visit the BiotechMashup Blog
Best upcoming scoops - Health
- Recycling Manufacturer
- Right hand or left? How the brain solves a perceptual puzzle
- Gene therapy boosts brain repair for demyelinating diseases
- Adolescent Binge Drinking Leads to Changes in Alcohol Drinking, Anxiety, and Amygdalar Corticotropin Releasing Factor Cells in A
- S-LOCUS EARLY FLOWERING 3 Is Exclusively Present in the Genomes of Short-Styled Buckwheat Plants that Exhibit Heteromorphic Self